Introduction
The fos-related antigen-2 (fra-2) gene encodes a member of the AP-1 family of transcriptional regulators, which is comprised of proteins related to the products of two proto-oncogenes, c-fos and c-jun (reviewed in Foletta, 1996) . The 46 kDa Fra-2 protein was originally identi®ed in chicken embryo ®broblasts through cross-reaction with an antiserum directed against c- Fos (Nishina et al., 1990) . Genomic and/or cDNA clones have now been isolated for chicken (Nishina et al., 1990) , human (Matsui et al., 1990) and mouse (Foletta et al., 1994) fra-2 and the gene structure is well-conserved across evolution, as is the encoded protein.
In cultured cells, fra-2 gene expression can be induced in response to serum, phorbol ester, elevated cAMP and calcium ionophore (reviewed in Foletta, 1996) . Serum induction of fra-2 expression in ®broblasts is delayed and is of longer duration than the rapid and transient induction pro®le that is characteristic of c-fos, with peak mRNA accumulation at 1 ± 2 h post-stimulation and high expression maintained for at least 5 h . Fra-2 appears to be involved in both the G 0 -to-G I transition phase of the cell cycle and also in asynchronous cell growth Bravo, 1991, 1992) .
The pattern of fra-2 expression in vivo is unlike other fos family members, with high levels of mRNA present in many animal tissues (Foletta et al., 1994) . Ovary and stomach have particularly high levels of fra-2 expression, and the mRNA is also readily detectable by Northern blotting in brain, heart, lungs, and small and large intestine. Lower levels of expression occur in kidney, testis, spleen, thymus and liver. Fra-2 expression is also detected in a range of embryonic tissues during organogenesis, with maximal expression between 14.5 and 18.5 days pc (Carrasco and Bravo, 1995) .
Like other members of the Fos family of proteins, Fra-2 can form heterodimeric complexes with all members of the Jun family (Suzuki et al., 1991) . These complexes will bind with high anity to the AP-1 consensus binding site and can in¯uence transcriptional activation either positively or negatively, depending upon the dimerization partner and the target promoter. For example, Fra-2/Jun complexes will suppress transactivation by c-Jun homodimers, whereas Fra-2/JunD complexes possess greater transactivational activity than JunD alone (Suzuki et al., 1991) . Despite signi®cant structural similarities between Fos family members, the Fra-2 protein does not possess a potent transactivation domain that is present in the C-terminal region of c-Fos and FosB (Suzuki et al., 1991; Wisdom and Verma, 1993) . This could account for the weaker activation properties demonstrated by the Fra-2 protein compared to some other family members.
Perhaps as a re¯ection of this dierence, overexpression of the Fra-2 protein results in only weak transformation of chicken embryo ®broblasts (CEF) and no transformation of rat ®broblast lines (Nishina et al., 1990; Wisdom and Verma, 1993; Foletta et al., 1994) , while both c-Fos and FosB strongly transform ®broblasts in culture (reviewed in Foletta, 1996) . To date, no transforming viruses have been identi®ed that carry the fra-2 gene, but a number of human cancer cell lines have signi®cantly elevated levels of fra-2 mRNA (Matsui et al., 1990) . Interestingly, several oncogenes, namely v-yes, v-fps, c-Ha-ras and activated c-raf, cause an elevation in fra-2 expression . The Fra-2 protein is a substrate for phosphorylation by the MAP kinase ERK2, and in v-src transformed cells there is an increase in both ERK2 activity and in the phosphorylation of the Fra-2 protein (Murakami et al., 1997) . It has been suggested that phosphorylation of Fra-2 may convert it from an inecient transcriptional activator into an active one. Thus, while it seems possible that elevated levels and/or increased phosphorylation of Fra-2 may contribute to transformation caused by over-expression of other genes, there is little evidence that fra-2 is itself an oncogene. To address this question more directly, we have generated transgenic mice that overexpress Fra-2 in a wide variety of tissues, to determine whether deregulated fra-2 expression can cause tumours. Despite high level expression of the transgene in many tissues, no animals developed tumours over an 18 month period of time. The only phenotypic abnormalities observed in the transgenic animals were lower body weight compared to littermate controls and disruption of eye development. The latter was characterized by failure of eyelids to fuse during embryogenesis, anterior segment dysgenesis and occasional microphthalmia. There was also some evidence that Fra-2 may negatively regulate expression from its own promoter.
Results

Generation of transgenic mice over-expressing fra-2
The coding region of the mouse fra-2 cDNA was ligated into the pCMVb vector, from which the bgalactosidase gene had been excised, to generate the construct pCMV-mfra2 (Figure 1 ). Zygotes injected with linearised plasmid were re-implanted into pseudopregnant females, and litters were analysed for the presence of the transgene by PCR of tail DNAs using the CMV-5' and F2ex3c primers (Figure 1 ). Three transgenic founder animals (N 0 ) were identi®ed (6492, 6526 and 6536) and breeding programmes to the C57BL/6 strain were established for each line so that ospring could be analysed for expression of the transgene.
RNA was extracted from tissues taken from transgenic ospring of each line and analysed by Northern blotting. The predicted RNA species from the transgene was 1.2 kb and was easily distinguished from the endogenous fra-2 mRNA (approximately 6 kb). No expression of the transgene could be detected in any tissues from the 6526 line, which was the line determined to have the highest copy number of the transgene per cell (approximately 50 copies). This line was not analysed any further. The 6536 line had an intermediate number of transgene copies (20 ± 25 per cell) and displayed a limited pattern of expression of the transgene RNA. Highest expression was in bone and muscle (data not shown), but the animals displayed no obvious phenotype that correlated with the presence of the transgene.
The 6492 line had the lowest number of transgene copies (2 ± 5 per cell) but had the most widespread expression of the transgene (Figure 2) . Furthermore, three of the ®ve N 1 transgenic ospring from the ®rst litter of the 6492 founder had a distinctive eye abnormality. The eyes were small and recessed into the head, displayed visible corneal opacities and a mucous ocular discharge was frequently present. As not all of this ®rst litter displayed this phenotype, it was decided to treat each N 1 transgenic animal as a distinct sub-line and to analyse the ospring of each line separately. The ®ve N 1 lines were identi®ed as 6786, 6787, 6788, 6789 and 6792. Interestingly, the two N 1 transgenic animals that did not appear to have an eye defect (namely, 6788 and 6792) did produce N 2 transgenic ospring with visible eye abnormalities. Furthermore, post-mortem analysis on animal 6792 revealed corneal opacities on the eyes of this animal. Post-mortem was not possible for animal 6788, but it is likely that all of the N 1 transgenic animals did have some eye defect, with the least severe aictions being less apparent during cursory examination of the live animals. Outcrosses of transgenic animals to BALB/c mice produced the same eye abnormality phenotype, indicating that the results observed were not strainspeci®c (data not shown).
RNA from a range of tissues from each N 1 sub-line was analysed by Northern blotting. From this analysis, it was apparent that there were three distinct patterns of transgene expression, although there was a large degree of overlap in these patterns. Sub-lines 6786, 6787 and 6788 expressed the transgene in bone, heart, kidney, muscle, skin, large intestine, small intestine, stomach and eye ( Figure 2 and data not shown). The similarity in transgene expression patterns for these three N 1 sub-lines makes it unlikely that they are Figure 1 Schematic representation of the pCMV-mfra2 plasmid construct used to generate transgenic mice. The arrows indicate the location and direction of the oligonucleotide primers, CMV5' and F2Ex3c, used in PCR ampli®cations to identify transgenic mice (product size=1225 bp). The bracketed restriction sites denote sites lost during cloning. The HindIII restriction site was used to linearise the plasmid for microinjection Figure 2 Northern blot detection of pCMV-mfra2 transgene RNA in transgenic mouse tissues. Equal amounts of RNA extracted from the tissues were electrophoresed on denaturing gels, and nitrocellulose blots were hybridized with 32 P-labelled fra-2 cDNA probe. A control mouse stomach sample is shown in the ®rst lane for comparison. The arrows indicate the approximately 6 kb endogenous (E) fra-2 RNA and the 1.2 kb transgene (T) fra-2 RNA. The positions of the 28s and 18s RNA's are indicated. S(C)=control stomach, B=Bone, Br=Brain, K=Kidney, H=Heart, LI=Large Intestine, L=Liver, Lg=Lung, M=Muscle, P=Pancreas, Sk=Skin, SI=Small Intestine, Sp=Spleen, S=Stomach, T=Thymus, Te=Testes, E(l)=left Eye, E(r)=right Eye distinct lines. Expression of the transgene in sub-line 6789 was in a similar array of tissues, except that no expression was detected in the skin and signi®cant expression was detected in the spleen (data not shown). The 6792 sub-line had little or no expression in heart, kidney, muscle and large intestine, and was the only line to have expression in the pancreas (data not shown). All sub-lines had transgene expression in the eye. The reason for these distinct but overlapping patterns of transgene expression is not clear, since Southern blotting revealed that all sub-lines appeared to have the same integration site and copy number of the transgene (data not shown). However, this phenomenon of dierent patterns of transgene expression within the one line of animals has been reported previously (Furth et al., 1991) .
Fra-2 may regulate expression of its own promoter
Another interesting result came from the Northern blotting analysis. When comparing tissues taken from control and transgenic littermates, it was observed that the moderately high level of endogenous fra-2 mRNA detected in stomach was reproducibly reduced in the transgenic animals ( Figure 3 ). As there was signi®cant expression of the transgene in stomach, we postulated that Fra-2 protein synthesized from the transgenic fra-2 RNA might be down-regulating expression from the endogenous fra-2 promoter. No reciprocal downregulation of expression from the transgene construct would be expected, as that construct makes use of the CMV immediate-early promoter, not the fra-2 promoter. Similar reduction in the levels of endogenous fra-2 mRNA was not apparent in other tissues in which both endogenous and transgene fra-2 were being expressed.
Transgenic animals were smaller than littermate controls
Another feature of the transgenic animals, which became noticeable in the N 2 and subsequent generations, was that they appeared to be smaller than their non-transgenic littermates. Weight gain was recorded for several litters, representing a cross-section of all transgenic sub-lines, over a period of 2 ± 3 weeks. Over the period of data collection, the transgenic animals were anywhere from 5 ± 50% smaller than the littermate control animals (data not shown). This was the case for 100% of the female animals and for 53% of the male animals overall (P50.001), although in some sub-lines (e.g. 6789), 100% of the male transgenic animals were smaller than their littermate controls (P50.001).
Transgenic animals had disrupted eye development
Once each sub-line was established in the N 2 or N 3 generation, the presence of the transgene could be predicted by examination of the eyes of each animal, which were noticeably abnormal in transgenic animals. PCR of tail DNAs con®rmed the correlation of transgene presence and eye abnormality, although the degree of penetrance of the phenotype in each eye of the same animal could vary. It was observed that if one eye was more severely aected than the other, then this usually correlated with dierent levels of expression of transgene in the two eyes, with lower expression manifest in less aected eyes ( Figure 2 ).
Clinical examination of the eyes of several adult transgenic mice showed both diuse and focal corneal opacities which prevented examination of the ocular interior; microphthalmia was observed in a few animals. Histological examination of the eye of an adult transgenic mouse revealed the nature of the defect (Figure 4 ). The ocular anomaly was essentially one of anterior segment dysgenesis, characterized by corneal stromal abnormalities, absence of the corneal endothelium and Descemet's membrane, and extensive adherence of iridal tissue to the posterior surface of the cornea resulting in obliteration of the anterior chamber (compare Figure 4c and d). Numerous small blood vessels were present in the corneal stroma and this vascularization was accompanied by an increase in cellular elements. Also present in the mid-corneal stroma were focal calcium deposits (con®rmed by Von Kossa staining of histological sections; data not shown). In addition there was a focal corneal ectasia ± an out-pouching of thinned cornea lined internally by pigmented iridal tissue. Further serial sections revealed corneal epithelial hyperplasia and hyperkeratosis overlying both a stromal calcium deposit and a region of intra-corneal haemorrhage. Towards the limbus the corneal stroma and pigmented iridal tissue were fused and thrown into dysplastic folds and rosettes. The lens, vitreous, retina, choroid, sclera and optic nerve appeared normal in this animal. Histological sections occasionally revealed other more severe eye abnormalities such as microphthalmia and microphakia ( Figure  4e and f) .
In the mouse, eye structures begin to develop from embryonic day 8.5 (E8.5) and by E11.5 a doublelayered optic cup is clearly de®ned. The development of the eye continues until late in embryogenesis and Figure 3 Negative regulation of the endogenous fra-2 promoter in transgenic tissue. Equal amounts of RNA from transgenic and control stomach were electrophoresed on a denaturing gel and stained with ethidium bromide (right panel). Northern blots were hybridized with a 32 P-labelled fra-2 cDNA probe (left panel). The arrows indicate the approximately 6 kb endogenous (E) fra-2 RNA and the 1.2 kb transgene (T) fra-2 RNA. T=Transgenic, C=Control fra-2 transgenic mice JZ McHenry et al results from migration of tissues from various regions of the embryo, including surface ectoderm, neuroectoderm, neural crest and mesoderm. To determine when the development of transgenic eyes diverges from that of control eyes, female C57BL/6 mice that had been mated with transgenic males of the 6786 sub-line were sacri®ced at 11.5, 13.5, 14.5, 15.5, 16.5, 17.5 or 20.5 days post coitum and the embryos were collected.
Embryonic heads were sectioned for histology and other tissue was taken for crude DNA preparation to be used in PCR assays to determine transgenic status. Newborn and day-old pups were collected and sacri®ced for similar analysis.
Newborn animals and embryos at late stages of development could be readily identi®ed as transgenic by cursory examination, since the eyes appeared to be : 106for panels a, b, c, d , g, and h; 406for panels e, f, i and j
Indeed, histological examination of the eyes revealed that the most striking dierence between transgenic and control animals was the failure of the eyelids to fuse at any stage during ontogenesis in the transgenic embryos ( Figure 5 ). This ®rst became evident at E15.5, at which stage the developing eyelids of the control animals had fused, whereas there was no eyelid fusion in any of the transgenic embryos (compare Figure 5c and d) . Another signi®cant dierence at this stage involved the developing corneal layers. In control eyes there was a wellorganised corneal structure: anteriorly the corneal epithelium comprised one or two layers of cells of ectodermal origin, the corneal stroma consisted of ordered layers of mesenchymal cells, and a single layer of well-de®ned corneal endothelial cells lined the posterior surface (Figure 5e ). However, in the transgenic eyes the corneal stroma was less organised compared with controls and the corneal endothelial cell layer was not clearly discernible (Figure 5f ). Prior to E15.5 histological dierences between control and transgenic embryonic eyes were not readily apparent (compare Figure 5a and b) . By E17.5 there was still failure of eyelid fusion in the transgenic eyes and haemorrhage was frequently present within the palpebral ®ssure. The corneal epithelial cells appeared to be enlarged, the corneal stroma was relatively poorly dierentiated comprising greater numbers of mesenchymal cells, and the corneal endothelial layer could not be clearly distinguished. However, there was an interesting similarity between the transgenic and control animals which could be observed at E17.5. In control animals, there was signi®cant keratinization of the outer layer of the eyelid (Figure 5g ). Despite the failure of the eyelids to fuse in transgenic animals, keratinization of the outer layer of the open eyelids could still be observed ( Figure  5 h), indicating that these cells may have lost their ability to respond to proliferation signals, but they had retained their ability to respond to other extracellular cues.
In neonatal transgenic animals lid fusion had failed and the palpebral ®ssure contained an in¯ammatory in®ltrate comprising mainly polymorphonuclear cells (Figure 6) . A keratitis was evident with polymorphonuclear cells in®ltrating the posterior corneal stroma in some eyes and the entire cornea in others. There was often an accompanying hyperkeratosis of the corneal epithelium. The anterior chamber contained polymorphonuclear cells in addition to frank haemorrhage and a ®brinous exudate. Some in¯ammatory cells were also occasionally observed within the palpebral conjunctiva. One neonatal transgenic mouse showed typical changes, as described above, in one eye, whereas the fellow eye was microphthalmic with an apparently normal lens invested closely by highly dysplastic retinal tissue. Over-expression of fra-2 produced a similar phenotype to over-expression of TGFa Examination of the literature reveals that there are many instances of disruption of gene expression, in either transgenic or knockout animals, which result in some perturbation of normal eye development (reviewed in Gotz, 1995) . Some of the reported abnormalities are clearly very distinct from those observed in the present example following the overexpression of fra-2. However, there were striking similarities between the results reported here and those observed following over-expression of the TGFa gene in the lens (Reneker et al., 1995) . In that paper, the authors expressed TGFa speci®cally in the lens of transgenic animals under the control of the aA crystallin promoter. The animals had a range of eye abnormalities, including failure of the eyelids to fuse, thickening and disruption of the cornea, absence of corneal endothelium and Descemet's membrane and cellular in®ltration of the anterior chamber. The mice also showed lens and retinal abnormalities that were not observed in the fra-2 transgenic mice.
Although the results obtained with the two transgenic lines may be completely unrelated, we were interested to determine whether either result could explain the other; namely, is Fra-2 a downstream eector of TGFa signalling, or alternatively, is the TGFa gene a target for transcriptional regulation by complexes containing Fra-2? As a starting point, we analysed RNA from transgenic eyes in which the expression of the fra-2 transgene was readily detectable by Northern blotting. These RNA samples were subjected to RT ± PCR with TGFa-speci®c primers. Similar levels of ampli®cation product of correct size were generated from the control eye RNA and from RNA extracted separately from the left and right eyes of a transgenic animal (Figure 7a ). Although this does not rule out the possibility that TGFa is a target gene for transcriptional regulation by Fra-2, it suggests that over-expression of Fra-2 alone does not result in increased expression of TGFa.
To determine whether signalling by TGFa results in increased expression of fra-2, we used Swiss 3T3 ®broblasts and performed a time-course of stimulation with 25 ng/ml TGFa. As shown in Figure 7(b and c) , stimulation of serum-starved ®broblasts with TGFa resulted in pronounced induction of fra-2 mRNA expression within 1 h (Figure 7b ) and corresponding induction of Fra-2 protein (as well as increased phosphorylation of the protein) within 1 ± 2 h ( Figure  7c ).
Discussion
We have generated transgenic animals that overexpress the AP-1 transcription factor Fra-2 in a range of mouse tissues, with a view to determining the oncogenic potential of fra-2. In the present study, the high levels of fra-2 expression were apparently tolerated very well, even in tissues where endogenous fra-2 is normally expressed at very low levels, as there was no evidence of tumour development or perturbation of tissue function ± apart from the eye abnormalities discussed below ± in any of the transgenic mice up to 18 months of age. 
other members of the AP-1 family, and the results revealed signi®cant dierences in the oncogenic potential of the proteins involved. In the case of c-fos, over-expression of the gene under the control of either the metallothionein (MT) promoter (Ruther et al., 1987) or the H2-K b promoter (Grigoriadis et al., 1993) , combined with replacement of 3' UTR mRNAdestabilising sequences with a viral long terminal repeat (LTR) sequence, resulted in development of lesions on the long bones of the legs. The further development of these lesions into osteosarcomas was variable and may have depended upon the level of expression of the transgene.
In contrast to these ®ndings, transgenic mice carrying either the H2-fosBLTR or the H2-cjunLTR construct did not develop any phenotypic abnormalities or tumours, despite high level expression of the transgene in a broad range of tissues (Grigoriadis et al., 1993) . Given existing knowledge of these AP-1 family members, these results may have been unexpected. In the case of FosB, this protein has very similar structure to c-Fos (Zerial et al., 1989) , and is expressed at low levels in most adult tissues. FosB is a potent transactivator and strongly transforms fibroblasts in culture (Schuermann et al., 1991) , but clearly the elevation of fosB expression, even in inappropriate cell types, is not sucient to produce cellular transformation in vivo. Interestingly, a transforming virus carrying the fosB gene has never been identi®ed. However, jun was originally identi®ed in a transforming virus (Maki et al., 1987) , and therefore this gene has obvious oncogenic potential.
These results may indicate that there are other aspects of the function of some AP-1 proteins which need to be deregulated in order to cause tumours. In this regard, it is noteworthy that the v-jun oncogene has a mutation which converts the conserved cysteine residue in the DNA binding domain into a serine residue (and allows the protein to escape redox regulation of DNA binding), a C-terminal point mutation that changes the phosphorylation pro®le of the protein, and a mutation which deletes 27 amino acids at the N-terminal end of the protein that may be a target for post-translational modi®cation (Nishimura and Vogt, 1988; Oehler et al., 1993 , and references therein). These mutations result in a protein (v-Jun) that is tenfold more ecient in transforming ®broblasts than is the wild-type (c-Jun) protein.
In this context, perhaps it is not surprising that overexpression of Fra-2 did not result in tumour development. The endogenous fra-2 gene is normally expressed at quite high levels in a number of tissues, and there may be very tight regulation of the function of the Fra-2 protein. This maybe in the form of some kind of posttranslational modi®cation (for example, phosphorylation by a kinase which is only active at certain times during the cell cycle), or alternatively, by limiting the function of Fra-2 through the dimerization partners available to interact with it. Thus, c-fos may be the exception in the AP-1 family, in that deregulation of expression of wild-type protein is sucient to convert this transcription factor into an oncogene.
Tumour development, of course, is only one of many possible manifestations of disrupted gene expression, and the discussion regarding the oncogenic potential of Fra-2 also relates to the more general result that, despite high levels of expression of the fra-2 transgene in many tissues (some of which normally express fra-2 and some of which do not), it was only in the eyes that any phenotypic eect of this expression was observed. This result suggests that in most cells, it is not the level of Fra-2 expression that is the limiting factor determining the downstream consequences of the presence of this AP-1 component. Thus, over-expression of Fra-2 produced a discernible outcome only in cells in which other factors were not limiting. Presumeably such a situation existed during development of the eye, thereby resulting in disruption of this process in the transgenic animals.
Perturbations of ocular ontogenesis were evident by embryonic day 15.5 (E15.5), at which time abnormalities of corneal dierentiation and failure of eyelid fusion could be observed. In embryonic transgenic eyes the anomalous dierentiation of the corneal stromal and endothelial cell layers was followed by in®ltration of in¯ammatory cells into the cornea and anterior chamber. It is likely that the anterior segment dysgenesis present in most adult transgenic eyes (which was characterized by obliteration of the anterior chamber, extensive adhesion of iris tissue to the posterior surface of the cornea, absence of corneal endothelium and Descemet's membrane, focal corneal calcium deposition and vascularization) was a consequence of this neonatal keratitis. Occasional transgenic eyes were severely aected and showed abnormalities associated with microphthalmia.
The absence of eyelid fusion in the transgenic animals may indicate that the over-expression of fra-2 disrupted the normal proliferation of cells within the surface ectoderm which must occur to allow eyelid fusion. This raises the interesting possibility that the contribution of Fra-2 to cellular function in some circumstances is anti-proliferative. This provides an alternative explanation for the lack of tumour formation, and could also explain the smaller size of the transgenic mice compared to littermate controls. An anti-proliferative function of Fra-2 could be mediated by one or more of the following mechanisms: (i) up-regulating the expression of genes that encode proteins with anti-proliferative functions; (ii) down-regulating the expression of genes that encode proteins which promote proliferation; (iii) competing for complex formation and/or DNA binding sites with other transcription factors and thereby interefering with the function of those complexes.
Another observation that might provide some insight into normal mechanisms of Fra-2 function is the apparent negative regulation of its own promoter in some circumstances. The down-regulation of endogenous fra-2 gene expression was only observed in stomach, despite the fact that other tissues had expression of both endogenous and transgene fra-2. There are two possible explanations for this: (i) only in stomach were both the endogenous gene and the transgene being expressed in the same cells within the tissue; (ii) only in stomach were the conditions (in terms of dimerization partner, protein modi®cations, etc) permissive for down-regulation of the fra-2 promoter by Fra-2 protein. In this second case, this would suggest that Fra-2 does not down-regulate its own promoter in all cell types in which it is expressed.
The fra-2 gene has an AP-1 site in its promoter region, immediately downstream of the start site of transcription (Foletta et al., 1994) and this site can be bound by a range of AP-1 protein complexes. Interestingly, in transient transfection assays reporter constructs containing the fra-2 promoter region are down-regulated by co-transfected Fra-2/Jun AP-1 complexes (VC Foletta and DR Cohen, unpublished results).
The interesting similarity between the eye abnormalities observed in the fra-2 transgenic animals reported here and a previous report on the eects of overexpression of TGFa in the eye, led us to investigate a possible relationship between these two signalling molecules. Expression of fra-2 was shown to be upregulated by TGFa treatment of ®broblasts in vitro, indicating that Fra-2 may be a downstream eector of TGFa signalling. Thus, at least some of the phenotypic abnormalities observed in the eyes of the TGFa transgenic animals may be explained by the upregulation of fra-2 expression.
Further questions of interest will be to determine how up-regulation of fra-2 expression may disrupt normal eye development. The major possibilities are (i) that over-expressed Fra-2 alters the expression of a set of target genes directly regulated by Fra-2, and/or (ii) that increased levels of Fra-2 alters a critical balance of proteins that interact with each other, thereby impacting on the expression of genes not directly regulated by Fra-2. With regards to possible target genes, interesting candidates might include genes encoding cellular migration factors and chemoattractant molecules, which could contribute to the abnormal cellular in®ltration of the corneal stroma that was observed. In terms of altered equilibria of protein-protein interactions, there are a number of obvious candidates, such as Jun family proteins and other b-zip transcription factors known to interact with AP-1 components. In addition, novel interactions between AP-1 proteins and other classes of transcription factors are continually being discovered, and some of these could be relevant to the phenotypic abnormalities observed in the fra-2 transgenic mice. For example, the basic ± helix ± loop ± helix family of transcription factors which also possess a leucine zipper dimerization domain (bHLH-Zip) includes such proteins as FIP, which interacts with c-Fos (Blanar and Rutter, 1992) , and USF, which interacts with Fra-1 (Pognonec et al., 1997) . The microphthalmia gene (mitf) is a member of this family (Hodgkinson et al., 1993; Hughes et al., 1993) . It is normally expressed in the retinal pigment epithelium (r.p.e.) of the eye (a structure that gives rise to the posterior leaf of the iris) from day E13.5, and mutations in the Mitf gene give rise to a number of abnormalities, including microphthalmia. Thus, the interesting phenotype of the fra-2 transgenic animals has provided insights into signalling pathway relationships and has suggested new avenues of investigation in the search for functional transcription factor interactions in vivo.
Materials and methods
Plasmid construction and generation of transgenic mice
The pCMVb vector (Stratagene) was digested with NotI to remove the b-galactosidase gene. The NotI overhang of the vector was ®lled in to permit blunt-end cloning of a 1.0 kb mouse fra-2 cDNA fragment that had been generated by EcoRI and HindIII digestion of pGEMZfra-2 (Foletta et al., 1994) followed by T4 DNA polymerase ®ll-in of the cohesive ends. The resulting plasmid was called pCMVmfra2. The 4.8 kb pCMV-mfra2 plasmid was linearized with HindIII and puri®ed by gel electrophoresis, followed by electroelution and ethanol precipitation. The puri®ed DNA was microinjected into zygotes derived from C57BL/ 6 F 1 mice fertilized by (C57BL/6 X SJL1) males. Embryos were implanted into pseudo-pregnant C57BL/6 X BALB/c foster mothers. Litters were screened by PCR analysis of tail DNA, using the primers CMV5': 5'-CGTCAATGGG-TGGAGTATTTACGG and F2Ex3c: 5'-CGCCTGCAGC-TTCTCTGTCAGCTC, a combination that generates an ampli®cation product of 1225 bp only if the transgene is present.
RNA extraction and Northern blotting
Tissue samples were collected from mice and immediately frozen in 95% hexane. Samples were either used immediately or stored at 7708C until required. The QIAGEN RNeasy kit was employed for isolation of total RNA; tissues were homogenized in 1 ml of lysis buer using a small Polytron probe and the RNA extraction procedure was performed according to the manufacturer's instructions. RNA concentration was determined by optical density at 260 nm. For Northern analysis, 5 mg of each total RNA sample was electrophoresed under denaturing conditions on 0.8% agarose/16MOPS/2.2 M formaldehyde gels. The gels were blotted overnight onto Hybond-C nitrocellulose (Amersham) in 206SSC. The ®lters were pre-hybridized and then hybridized overnight with a PCR-generated 32 P-dCTP-labelled fra-2 probe as described in (Foletta et al., 1994) . After washing, the hybridization signals were detected using X-ray ®lms and intensifying screens.
Histological analysis
Tissues were isolated from mice and directly ®xed in 10% neutral buered formalin for at least 24 h. Fixed and dehydrated tissues were embedded in wax prior to sectioning. Tissues for histological analysis were stained with hematoxylin and eosin (H&E) stain.
Western blotting
Protein extracts were prepared using the method of Schreiber et al., (1989) . For Western blotting, proteins were resolved by SDS-polyacrylamide gel electrophoresis on 10% polyacrylamide gels and transferred by electroblotting to nitrocellulose. Filters were pre-blocked with 5% BSA (in PBS) and incubated with aF2-FL polyclonal antibody (raised against recombinant Fra-2 protein; DR Cohen, unpublished) followed by donkey anti-rabbit immunoglobulin G antibody conjugated to horseradish peroxidase (Amersham). The protein bands were visualized using the ECL Western blotting detection system (Amersham).
Cell culture and TGFa stimulation
Swiss 3T3 ®broblasts were cultured in DMEM (Sigma) containing 10% fetal calf serum (FCS). When the cells were sub-con¯uent, the medium was replaced with DMEM lacking FCS and 48 h later the cells were stimulated for 1, 2, 4 or 8 h with 25 ng/ml TGFa (ICN Biochemicals Inc). Protein or RNA was prepared from the cells as described.
